PSNL NASDAQ
Personalis, Inc.
1W: +0.2%
1M: -2.1%
3M: +36.2%
YTD: +103.6%
1Y: +65.1%
3Y: +1586.4%
5Y: -19.5%
$15.98
+0.10 (+0.63%)
Pre-Market: $15.93 (-0.05, -0.28%)
Weekly Expected Move ±2.0%
$15
$16
$16
$16
$16
Credit Risk of going bust: lower than 76% of companies Debt: 2.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Personalis, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $1.71B.
Distance to default 8.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $898K (short-term plus half of long-term), stock volatility 83.7%; Altman Z'' -2.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Personalis, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $1.71B.
Distance to default 8.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $898K (short-term plus half of long-term), stock volatility 83.7%; Altman Z'' -2.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#30
of 91
Medical - Diagnostics & Research
Technical Signal Map
14 Bullish
2 Neutral
2 Bearish
PSNL
$1.7B
Personalis, Inc.
NEUTRAL
+1
VCYT
$3.9B
Veracyte, Inc.
BULLISH
+100
MRCHF
$1.3B
H.U. Group Holdings, Inc.
BULLISH
+100
MYGN
$560M
Myriad Genetics, Inc.
BULLISH
+87
BLLN
$5.1B
BillionToOne, Inc.
BULLISH
+84
DSRLF
$4.4B
DiaSorin S.p.A.
BULLISH
+66
CDNA
$3.6B
CareDx, Inc
BULLISH
+66
IDGXF
$340M
Integrated Diagnostics Holdings plc
BULLISH
+65
CSTL
$1.0B
Castle Biosciences, Inc.
BULLISH
+59
GRAL
$5.9B
GRAIL Inc.
BULLISH
+53
OPK
$1.2B
OPKO Health, Inc.
BULLISH
+53
SKHHY
$6.5B
Sonic Healthcare Limited
BULLISH
+43
RDNT
$5.5B
RadNet, Inc.
BULLISH
+43
SHC
$5.2B
Sotera Health Company
LEAN BULL
+27
NEO
$2.2B
NeoGenomics, Inc.
LEAN BULL
+10
FLGT
$550M
Fulgent Genetics, Inc.
NEUTRAL
-8
WGS
$1.7B
GeneDx Holdings Corp.
BEARISH
-42
VIMGF
$1.5B
Vimian Group AB (publ)
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| PSNL Personalis, Inc. | $1.7B | -14.7 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | NEUTRAL | 65.1 |
| VCYT Veracyte, Inc. | $3.9B | 34.9 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| MRCHF H.U. Group Holdings, Inc. | $1.3B | 21.8 | 7.2 | 3.3 | 2.5 | 1.8 | 9 | BULLISH | -7.4 |
| MYGN Myriad Genetics, Inc. | $560M | -5.3 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -22.8 |
| BLLN BillionToOne, Inc. | $5.1B | 165.3 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.4 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 10.2 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| CSTL Castle Biosciences, Inc. | $1.0B | -52.3 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 40.8 |
| GRAL GRAIL Inc. | $5.9B | -15.4 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| OPK OPKO Health, Inc. | $1.2B | -16.9 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | BULLISH | 7.3 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.3 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | BULLISH | -5.9 |
| RDNT RadNet, Inc. | $5.5B | -275.9 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BULLISH | -11.8 |
| SHC Sotera Health Company | $5.2B | 32.3 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| NEO NeoGenomics, Inc. | $2.2B | -43.5 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | LEAN BULL | 61.9 |
| FLGT Fulgent Genetics, Inc. | $550M | -7.3 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | NEUTRAL | -12.8 |
| WGS GeneDx Holdings Corp. | $1.7B | -17.2 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -51.3 |
| VIMGF Vimian Group AB (publ) | $1.5B | 48.7 | 5.4 | 6.4 | 7.4 | 8.9 | 7 | BEARISH | -8.0 |
| PSNL Personalis, Inc. | $1.7B | -14.7 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | NEUTRAL | 65.1 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| ARDT Ardent Health Inc. | $1.7B | 21.5 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -22.3 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 16.1 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 31.8 |
| LWSCF Sienna Senior Living Inc. | $1.6B | 38.9 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | BULLISH | 7.9 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.6 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.2 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 15.3 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.5 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.3 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 51.4 |
| OMCL Omnicell, Inc. | $1.7B | 43.0 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 18.2 |
| TSMRF Tsumura & Co. | $1.7B | 9.1 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.1 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -32.5 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.4 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.8 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| STSEY Stratec SE | $1.7B | -573.8 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | LEAN BEAR | -17.8 |
| ALHC Alignment Healthcare, Inc. | $1.7B | 40.4 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -54.0 |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 14.7 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | BEARISH | -24.5 |
| NVCR Novocure Ltd | $1.7B | -11.2 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 6.3 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.1 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| FDMDF 4DMedical Limited | $1.6B | -8.7 | -174.5 | 43.4 | -1194.8 | 20.5 | 3 | BEARISH | 94.2 |
| PSNL Personalis, Inc. | $1.7B | -14.7 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | NEUTRAL | 65.1 |
| CAI Caris Life Sciences, Inc. | $9.1B | 90.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| HNGE Hinge Health, Inc. | $9.0B | 84.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 129.6 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.5 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 32.8 |
| ALKS Alkermes plc | $7.3B | 110.0 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 48.7 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 43.1 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 103.2 |
| BLCO Bausch + Lomb Corporation | $6.2B | -36.8 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 13.5 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 62.4 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BULLISH | 129.1 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -6.0 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.8 |
| LFST LifeStance Health Group, Inc. | $4.9B | 100.6 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 151.9 |
| VCYT Veracyte, Inc. | $3.9B | 34.9 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| ATRC AtriCure, Inc. | $3.0B | 289.9 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.9 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| GNNDY GN Store Nord A/S | $2.4B | -29.7 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -5.1 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.3 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SGRY Surgery Partners, Inc. | $2.1B | -33.9 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 2.4 |
| SEPN Septerna Inc | $1.9B | -81.7 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| CERT Certara, Inc. | $1.6B | -24.7 | -6.7 | 0.6 | -59.3 | 0.7 | 6 | BULLISH | -13.5 |
| MRCHF H.U. Group Holdings, Inc. | $1.3B | 21.8 | 7.2 | 3.3 | 2.5 | 1.8 | 9 | BULLISH | -7.4 |
| LTGHY Life Healthcare Group Holdings Limited | $1.1B | 2.7 | 68.5 | 10.7 | 6.2 | -3.0 | 4 | BULLISH | 14.5 |
| VSTM Verastem, Inc. | $910M | -4.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 27.0 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -16.2 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| CTKB Cytek Biosciences, Inc. | $730M | -9.6 | -23.0 | -40.8 | -25.3 | 5.4 | 3 | BULLISH | 40.4 |
| RCEL Avita Medical Inc. | $390M | -11.1 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 305.0 |
| HQY HealthEquity, Inc. | $8.6B | 36.0 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 4.5 |
| PACS PACS Group, Inc. | $7.5B | 28.1 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 277.8 |
| SSMXY Sysmex Corporation | $7.4B | 30.4 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.5 |
| DOCS Doximity, Inc. | $6.0B | 37.3 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.3 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| WAY Waystar Holding Corp. | $5.5B | 38.9 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -28.1 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.8 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 92.0 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.5 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 64.0 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -23.7 |
| VCEL Vericel Corporation | $2.2B | 90.1 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 77.4 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.4 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 142.2 |
| AMN AMN Healthcare Services, Inc. | $1.9B | 17.3 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 120.8 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 16.1 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 31.8 |
| ARDT Ardent Health Inc. | $1.7B | 21.5 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -22.3 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| GDRX GoodRx Holdings, Inc. | $1.2B | 66.2 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BULLISH | -11.9 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| HSTM HealthStream, Inc. | $1.1B | 47.8 | 6.0 | 6.5 | 8.0 | 8.8 | 8 | BULLISH | 30.1 |
| CBLL CeriBell, Inc. | $1.0B | -15.5 | -43.9 | -263.7 | -68.6 | 69.3 | 3 | BULLISH | 111.2 |
| BVS Bioventus Inc. | $1.0B | 17.9 | 28.0 | 21.3 | 21.8 | 3.1 | 7 | BULLISH | 107.8 |
| SIBN SI-BONE, Inc. | $960M | -63.1 | -8.3 | -32.2 | -7.3 | 15.3 | 6 | BULLISH | 38.4 |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| PHR Phreesia, Inc. | $790M | 71.4 | 3.1 | 16.7 | 1.5 | 12.9 | 4 | BULLISH | -47.7 |
| AONC American Oncology Network, Inc. | $640M | -29.7 | 5.6 | -14.7 | 0.3 | 37.5 | 6 | BULLISH | 132.2 |
| ENTX Entera Bio Ltd. | $510M | -8.8 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 37.8 |
| MOBI Mobia Medical, Inc. Common Stock | $350M | — | — | — | — | — | — | BULLISH | — |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.8 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.5 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| LWSCF Sienna Senior Living Inc. | $1.6B | 38.9 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | BULLISH | 7.9 |
| AHG Akso Health Group | $1.1B | -21.0 | -50.1 | -44.9 | -546.5 | 22.7 | 4 | BULLISH | -17.1 |
| PRME Prime Medicine, Inc. | $670M | -4.0 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | -18.4 |
| MYGN Myriad Genetics, Inc. | $560M | -5.3 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -22.8 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.7 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -14.5 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.7 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 12.1 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.2 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| BLLN BillionToOne, Inc. | $5.1B | 165.3 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.8 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| LEGN Legend Biotech Corporation | $3.6B | -43.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| TNDM Tandem Diabetes Care, Inc. | $1.2B | -20.7 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BULLISH | 28.6 |
| TDOC Teladoc Health, Inc. | $1.1B | -6.5 | -13.0 | -8.7 | -6.4 | -2.1 | 5 | BULLISH | -31.8 |
| STAA STAAR Surgical Company | $1.1B | 302.0 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | BULLISH | -8.0 |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | $1.1B | -31.1 | -3.9 | 0.1 | 1.0 | — | 3 | BULLISH | — |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -8.8 |
| HAE Haemonetics Corporation | $5.4B | 58.2 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 134.1 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.6 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| PGNY Progyny, Inc. | $2.2B | 28.6 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.2 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.3 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| KIDS OrthoPediatrics Corp. | $640M | -16.7 | -11.4 | -4.6 | -10.2 | 14.5 | 6 | BULLISH | 39.9 |
| MASS 908 Devices Inc. | $470M | -13.3 | -25.1 | -103.8 | -74.0 | 4.6 | 5 | BULLISH | 45.2 |
| AVHHL AVITA Medical, Inc. | $360M | -11.1 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 149.1 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.6 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| AZTA Azenta, Inc. | $1.6B | -14.2 | -7.7 | -1.4 | 1.5 | 1.5 | 4 | BULLISH | 21.1 |
| GRRMF Gerresheimer AG | $1.2B | -2.8 | 1.6 | 2.2 | -2.3 | 11.8 | 4 | BULLISH | -27.1 |
| ENOV Enovis Corporation | $1.2B | -1.1 | -54.3 | -13.5 | -0.2 | 4.9 | 4 | BULLISH | -34.4 |
| TDVXF Dynavox Group AB (publ) | $900M | 28.1 | 39.7 | 17.2 | 12.8 | 8.8 | 8 | BULLISH | -22.7 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.8 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| GNGBY Getinge AB (publ) | $7.3B | 26.0 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.6 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.8 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -40.7 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 52.7 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -45.5 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 194.2 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.5 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.2 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 15.3 |
| AGL Agilon Health, Inc. | $1.5B | -5.9 | -78.9 | -273.7 | 1.2 | 0.3 | 6 | BULLISH | 273.6 |
| NWKHY Netcare Limited | $1.4B | 12.4 | 16.9 | 8.1 | 6.7 | 5.0 | 7 | BULLISH | 59.5 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.3 | -25.8 | -768.9 | — | — | 2 | BULLISH | 148.2 |
| OABIW OmniAb, Inc. | $1.1B | -13.8 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -17.6 |
| ARRJF Arjo AB (publ) | $920M | 25.5 | 4.6 | 4.4 | 2.0 | -2.0 | 6 | BULLISH | 3.1 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.9 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 68.7 |
| VMD Viemed Healthcare, Inc. | $370M | 25.7 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 39.9 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.6 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| EVH Evolent Health, Inc. | $540M | -1.0 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BULLISH | -43.4 |
| QDEL QuidelOrtho Corporation | $940M | -0.9 | -45.9 | -13.7 | -14.7 | 0.1 | 4 | BULLISH | -55.5 |
| PACB Pacific Biosciences of California, Inc. | $660M | -5.7 | -929.3 | -29.4 | -114.7 | 2.0 | 2 | BULLISH | 21.3 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.3 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 136.9 |
| ERAS Erasca, Inc. | $5.0B | -16.0 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| ESAIY Eisai Co., Ltd. | $9.2B | 33.8 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.7 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.1 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.4 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 14.8 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.1 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.2 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 1.8 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.6 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | -0.3 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| XNCR Xencor, Inc. | $1.9B | -13.8 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.3 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 51.4 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 171.0 |
| BBNX Beta Bionics, Inc. | $860M | -11.4 | -26.2 | -79.6 | -73.1 | 191.1 | 3 | BULLISH | 2.1 |
| PBYI Puma Biotechnology, Inc. | $570M | 20.4 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 108.8 |
| CV CapsoVision, Inc. | $370M | -10.7 | -226.6 | -73.0 | -205.4 | — | 2 | BULLISH | 37.8 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.1 | -24.4 | -231.4 | — | — | 3 | BULLISH | 14.0 |
| XRAY DENTSPLY SIRONA Inc. | $1.9B | -3.4 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | BULLISH | -27.6 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 10.2 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| NBTX Nanobiotix S.A. | $1.5B | -28.2 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 14.7 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.6 | -39.6 | 55646.0 | — | — | 4 | BULLISH | 511.6 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.7 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -52.0 |
| CSTL Castle Biosciences, Inc. | $1.0B | -52.3 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 40.8 |
| PHAR Pharming Group N.V. | $710M | 82.8 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -12.7 |
| CARL Carlsmed, Inc. | $400M | -11.3 | -43.8 | -122.7 | -55.5 | — | 2 | BULLISH | 14.4 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.5 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.0 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.8 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -2.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.8 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| PCRX Pacira BioSciences, Inc. | $1.4B | 103.4 | 2.0 | 1.8 | 2.4 | 5.7 | 8 | BULLISH | 67.4 |
| KHTRF Knight Therapeutics Inc. | $810M | 76.7 | 1.9 | 2.6 | -2.3 | 42.4 | 8 | BULLISH | 98.5 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 40.0 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 15.9 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| GRAL GRAIL Inc. | $5.9B | -15.4 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| AMBBY Ambu A/S | $3.2B | 41.8 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.1 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -16.0 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.2 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| OMCL Omnicell, Inc. | $1.7B | 43.0 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 18.2 |
| VTRLY Vitrolife AB (publ) | $1.4B | -3.1 | -46.2 | -41.3 | 14.3 | -2.0 | 5 | BULLISH | -34.0 |
| OPK OPKO Health, Inc. | $1.2B | -16.9 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | BULLISH | 7.3 |
| EMBC Embecta Corp. | $380M | 4.4 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | BULLISH | -53.7 |
| CASBF CanSino Biologics Inc. | $1.4B | 399.2 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -25.5 |
| REPL Replimune Group, Inc. | $1.1B | -4.1 | -134.3 | -1055.2 | — | — | 1 | BULLISH | 48.3 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.5 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 28.9 | 16.8 | 25.6 | 24.2 | 11.8 | 8 | BULLISH | -5.8 |
| ABSI Absci Corporation | $1.6B | -13.2 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 147.5 |
| CRON Cronos Group Inc. | $1.2B | 18.1 | 6.5 | 5.4 | 60.5 | 72.9 | 7 | BULLISH | 34.1 |
| PRCT PROCEPT BioRobotics Corporation | $1.1B | -10.2 | -30.2 | -47.6 | -28.4 | 22.7 | 2 | BULLISH | -43.4 |
| CRMD CorMedix Inc. | $610M | 3.3 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -28.4 |
| IOBCF Ion Beam Applications S.A. | $550M | 19.9 | 20.6 | 14.0 | 2.9 | 7.0 | 5 | BULLISH | 39.5 |
| TCMD Tactile Systems Technology, Inc. | $540M | 21.5 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BULLISH | 55.4 |
| NRC NRC Health | $490M | 71.9 | 42.0 | 9.9 | -9.3 | -0.2 | 6 | BULLISH | 48.3 |
| SI Shoulder Innovations, Inc. | $410M | -11.3 | -28.2 | -69.1 | -59.1 | — | 1 | BULLISH | 57.7 |
| MTHRY M3, Inc. | $8.2B | 27.1 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -17.1 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.6 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| ESTA Establishment Labs Holdings Inc. | $1.9B | -51.2 | -175.3 | -6.9 | -17.4 | 38.6 | 5 | BULLISH | 36.4 |
| EKTAY Elekta AB (publ) | $2.2B | -61.6 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 9.3 |
| BRKR Bruker Corporation | $8.8B | -86.9 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 55.9 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.3 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | BULLISH | -5.9 |
| RDNT RadNet, Inc. | $5.5B | -275.9 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BULLISH | -11.8 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BULLISH | -28.1 |
| KMDA Kamada Ltd. | $450M | 21.0 | 8.4 | 11.0 | 16.9 | 13.2 | 7 | BULLISH | 17.2 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -33.0 |
| PAHC Phibro Animal Health Corporation | $1.6B | 15.6 | 29.7 | 13.2 | 5.5 | 17.1 | 7 | BULLISH | -9.1 |
| IMCR Immunocore Holdings plc | $1.6B | -177.3 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| CNMD CONMED Corporation | $1.5B | 25.5 | 5.5 | 5.2 | 6.7 | 3.4 | 7 | BULLISH | -1.3 |
| PNTG The Pennant Group, Inc. | $1.5B | 44.3 | 9.6 | 5.5 | 3.0 | 37.9 | 6 | BULLISH | 72.8 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -12.1 | -114.6 | 616.3 | — | — | 2 | BULLISH | 26.3 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.1 | -67.4 | 2902.7 | — | — | 1 | BULLISH | 25.3 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SHWGF Shandong Weigao Group Medical Polymer Company Limited | $1.9B | 9.4 | 5.6 | 7.4 | 11.3 | 2.2 | 6 | BULLISH | -39.1 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $460M | 76.2 | 1.9 | -0.5 | -19.7 | 66.6 | 4 | BULLISH | -17.1 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.0 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | BULLISH | -15.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BULLISH | -13.8 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 174.6 |
| EDIT Editas Medicine, Inc. | $370M | -3.5 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BULLISH | -30.1 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.8 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BULLISH | -1.1 |
| CSWYF China Shineway Pharmaceutical Group Limited | $760M | 5.9 | 19.9 | 46.7 | 21.6 | 1081.8 | 8 | BULLISH | 0.0 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 73.8 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 27.8 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.9 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| SHC Sotera Health Company | $5.2B | 32.3 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| SOPH SOPHiA GENETICS S.A. | $630M | -6.6 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | LEAN BULL | 77.4 |
| NGNE Neurogene Inc. | $370M | -4.9 | -45.3 | -111469.0 | — | — | 2 | LEAN BULL | -9.7 |
| CHEOY Cochlear Limited | $6.7B | 62.2 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | LEAN BULL | -48.2 |
| NVST Envista Holdings Corp | $3.8B | 40.0 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| SGHT Sight Sciences, Inc. | $500M | -16.2 | -48.4 | -145.7 | -19.0 | 9.3 | 4 | LEAN BULL | 71.0 |
| PTCHF PureTech Health plc | $390M | 157.9 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | LEAN BULL | -5.4 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -5.8 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | LEAN BULL | 46.0 |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 513.8 | -1.3 | 7.7 | 0.7 | 17.1 | 5 | LEAN BULL | -3.7 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.2 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.2 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| TSMRF Tsumura & Co. | $1.7B | 9.1 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| SWGHF Sawai Group Holdings Co., Ltd. | $1.3B | 22.7 | 4.3 | 4.6 | 4.7 | 11.4 | 4 | LEAN BULL | 0.0 |
| TWAPF Towa Pharmaceutical Co., Ltd. | $1.3B | 20.8 | 4.7 | 3.2 | 7.7 | 7.1 | 7 | LEAN BULL | 54.4 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $980M | 13.9 | 6.9 | 7.9 | 28.0 | -6.6 | 4 | LEAN BULL | 8.3 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.3 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -7.9 |
| VREX Varex Imaging Corporation | $780M | 35.2 | 4.6 | 7.6 | 7.5 | 5.3 | 6 | LEAN BULL | 54.0 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.6 | -15.3 | -6535.0 | — | — | 3 | LEAN BULL | 112.0 |
| NEOG Neogen Corporation | $2.7B | -49.2 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.5 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | LEAN BULL | 39.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| CERS Cerus Corporation | $470M | -66.3 | -10.8 | -7.4 | -5.1 | 15.1 | 5 | LEAN BULL | 56.9 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.2 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | LEAN BULL | 31.0 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | LEAN BULL | 15.7 |
| INNV Innovage Holding Corp. | $1.3B | -440.6 | -1.1 | -89.6 | 3.2 | 16.4 | 6 | LEAN BULL | 73.1 |
| COLL Collegium Pharmaceutical, Inc. | $750M | 15.0 | 17.6 | 9.4 | -7.5 | 14.3 | 6 | LEAN BULL | -34.8 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | LEAN BULL | — |
| GMRS GMR Solutions Inc. | $580M | — | — | — | — | — | — | LEAN BULL | — |
| CYDY CytoDyn Inc. | $380M | -5.0 | 57.8 | 24.6 | — | 100.0 | 4 | LEAN BULL | -16.2 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.5 | -46.6 | 137.5 | — | — | 3 | LEAN BULL | 82.1 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -9.0 | -45.3 | -2390.9 | — | — | 2 | LEAN BULL | 51.2 |
| STLN Starling Oncology, Inc. | $670M | — | — | — | — | — | — | LEAN BULL | — |
| PRTA Prothena Corporation plc | $420M | -10.6 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | LEAN BULL | -10.3 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -5.1 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BULL | 15.9 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.4 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | LEAN BULL | -10.9 |
| NEO NeoGenomics, Inc. | $2.2B | -43.5 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | LEAN BULL | 61.9 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.1 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -32.5 |
| IUSDF AS ONE Corporation | $1.0B | 19.1 | 12.2 | 13.4 | 8.1 | 5.7 | 6 | LEAN BULL | -39.5 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.1 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | NEUTRAL | -17.2 |
| MLAB Mesa Laboratories, Inc. | $720M | 150.3 | 2.7 | 4.4 | 4.7 | 3.0 | 8 | NEUTRAL | 63.6 |
| OFIX Orthofix Medical Inc. | $400M | -6.3 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | NEUTRAL | -39.2 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 17.3 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ICUI ICU Medical, Inc. | $4.2B | 136.0 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | NEUTRAL | 32.2 |
| CLCGY Clicks Group Limited | $3.1B | 15.5 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | NEUTRAL | -37.3 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.6 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | NEUTRAL | 34.7 |
| NPNKF Nippon Shinyaku Co., Ltd. | $1.6B | 7.2 | 11.6 | 12.5 | 20.6 | 12.8 | 4 | NEUTRAL | -1.1 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.4 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| OSCR Oscar Health, Inc. | $8.0B | 18.3 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | NEUTRAL | 62.6 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.4 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| PMI Picard Medical, Inc. | $730M | -0.3 | -1631.2 | -469.0 | -191.6 | — | 2 | NEUTRAL | 28.2 |
| BCHMF Bachem Holding AG | $6.8B | 42.0 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 20.9 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.2 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| TCHBF Tecan Group AG | $3.5B | -26.8 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | NEUTRAL | 45.2 |
| OSSFF Embla Medical hf. | $1.9B | 18.2 | 10.4 | 7.7 | 10.5 | 9.9 | 7 | NEUTRAL | -5.6 |
| CSSPF NIOX Group Plc | $380M | 41.1 | 10.8 | 13.0 | 24.6 | 3.5 | 7 | NEUTRAL | -2.3 |
| TXG 10x Genomics, Inc. | $9.3B | -132.2 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.8 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | NEUTRAL | 126.7 |
| HUMDF Hua Medicine (Shanghai) Ltd. | $300M | -18.4 | -10.3 | -30.2 | -8.0 | 73.9 | 3 | NEUTRAL | -26.1 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| NUTX Nutex Health, Inc. | $1.4B | 7.9 | 49.2 | 53.9 | 31.2 | 6.9 | 7 | NEUTRAL | 65.8 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 16.8 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.5 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | NEUTRAL | -30.7 |
| VHIBF Vitalhub Corp. | $340M | 62.1 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | NEUTRAL | -31.4 |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | NEUTRAL | — |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.2 | -13.7 | -105758.3 | — | — | 3 | NEUTRAL | -11.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 18.4 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.4 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.3 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | NEUTRAL | 10.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -67.9 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | NEUTRAL | 60.6 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | NEUTRAL | 50.4 |
| CHE Chemed Corporation | $6.7B | 24.2 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | NEUTRAL | 16.6 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.5 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | NEUTRAL | 46.7 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.8 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| FLGT Fulgent Genetics, Inc. | $550M | -7.3 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | NEUTRAL | -12.8 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.6 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 14.7 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | NEUTRAL | 4.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.2 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BEAR | -23.8 |
| AHCO AdaptHealth Corp. | $820M | -3.5 | -15.5 | -0.2 | -18.1 | 22.9 | 6 | LEAN BEAR | -37.6 |
| MCTA Charming Medical Limited Class A Ordinary Shares | $450M | — | — | — | — | — | — | LEAN BEAR | — |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 29.6 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | LEAN BEAR | 32.6 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.5 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.9 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| STSEY Stratec SE | $1.7B | -573.8 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | LEAN BEAR | -17.8 |
| SAFLY Safilo Group S.p.A. | $1.4B | 15.4 | 12.0 | 10.0 | 8.7 | -3.4 | 7 | LEAN BEAR | 40.1 |
| AGYTF Allergy Therapeutics plc | $760M | -4.3 | 3372.3 | -97.9 | -54.9 | 19.9 | 3 | LEAN BEAR | 36.4 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | LEAN BEAR | -25.4 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.6 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | LEAN BEAR | -3.2 |
| NPCE NeuroPace, Inc. | $440M | -22.8 | -122.1 | -39.6 | -27.2 | 11.6 | 4 | LEAN BEAR | 24.2 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | LEAN BEAR | 78.7 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | LEAN BEAR | 160.4 |
| AORT Artivion, Inc. | $1.1B | -384.9 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | LEAN BEAR | -47.1 |
| RSLBF RaySearch Laboratories AB (publ) | $510M | 31.9 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | LEAN BEAR | -35.8 |
| COGZF Cogstate Limited | $410M | 34.9 | 22.4 | 37.3 | 22.4 | -14.8 | 3 | LEAN BEAR | 44.9 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BEAR | -8.4 |
| CLOV Clover Health Investments, Corp. | $2.4B | -114.3 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | LEAN BEAR | 21.2 |
| JBIO Jade Biosciences, Inc. | $930M | -5.4 | -47.8 | 629.9 | — | — | 3 | LEAN BEAR | 47.4 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.4 | -50.3 | 1635.6 | — | — | 1 | LEAN BEAR | 91.2 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.5 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BEAR | 76.3 |
| ANGO AngioDynamics, Inc. | $520M | -15.5 | -19.2 | -20.5 | -8.8 | 8.2 | 5 | LEAN BEAR | -0.7 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | LEAN BEAR | -6.2 |
| JNDOF JINS HOLDINGS Inc. | $810M | 17.8 | 22.7 | 27.1 | 5.1 | 15.0 | 6 | LEAN BEAR | 51.6 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 603.3 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -70.9 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.2 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| MDRSF Medartis Holding AG | $1.4B | 76.5 | 5.5 | 0.7 | 3.2 | 29.6 | 6 | LEAN BEAR | 72.5 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BEAR | 22.2 |
| CELC Celcuity Inc. | $3.2B | -15.9 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -4.1 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -81.7 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | LEAN BEAR | 18.1 |
| TWST Twist Bioscience Corporation | $9.2B | -72.0 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -10.8 | -1773.6 | 55.8 | — | -100.0 | 4 | LEAN BEAR | 67.0 |
| LJUIF SSY Group Limited | $1.2B | 15.0 | 6.7 | 4.6 | 13.6 | -4.4 | 5 | LEAN BEAR | 0.0 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | LEAN BEAR | — |
| SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $690M | 66.0 | 2.8 | 2.7 | 7.0 | -0.3 | 6 | LEAN BEAR | 0.0 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | LEAN BEAR | -64.9 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 9.2 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| JXFGF Jinxin Fertility Group Limited | $730M | 26.6 | 1.9 | 1.8 | 7.8 | 1.4 | 7 | LEAN BEAR | 3.6 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| CLVSF CellaVision AB (publ) | $330M | 32.0 | 15.1 | 17.1 | 16.3 | -1.9 | 6 | LEAN BEAR | -27.4 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 119.7 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.1 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | LEAN BEAR | 0.0 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 19.6 |
| ASTH Astrana Health, Inc. | $1.9B | 44.6 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | LEAN BEAR | 10.9 |
| CLHLF COLTENE Holding AG | $330M | 19.8 | 16.1 | 12.5 | 3.6 | -2.5 | 5 | LEAN BEAR | -8.4 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.1 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | -10.5 |
| MDRX Veradigm Inc. | $830M | -7.1 | 4.3 | 7.0 | 6.2 | -39.7 | 5 | BEARISH | 0.0 |
| ARVN Arvinas, Inc. | $470M | 39.2 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -19.1 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.8 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -24.8 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| AXGN AxoGen, Inc. | $2.2B | -55.5 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | BEARISH | 106.2 |
| SNBIF SanBio Company Limited | $1.3B | -19.8 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| CVSGF CVS Group plc | $1.1B | 52.4 | 5.9 | 7.3 | 2.7 | -22.7 | 6 | BEARISH | 0.7 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| OVID Ovid Therapeutics Inc. | $420M | -4.7 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 38.6 |
| CYH Community Health Systems, Inc. | $410M | -1.3 | 19.9 | -79.1 | 1.7 | 77.2 | 5 | BEARISH | -30.7 |
| RZLT Rezolute, Inc. | $370M | -5.4 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -55.3 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.9 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| HCM HUTCHMED (China) Limited | $2.6B | 145.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BEARISH | -6.5 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.7 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 38.8 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.5 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -6.0 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| BPMUF Basilea Pharmaceutica AG | $960M | 17.0 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.2 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BEARISH | -16.9 |
| BOIRF Boiron S.A. | $550M | 12.5 | 7.2 | 7.8 | 2.0 | 97.0 | 5 | BEARISH | 10.5 |
| CTEV Claritev Corporation | $400M | -1.3 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | BEARISH | -67.5 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -9.1 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 6.2 |
| RYHTY Ryman Healthcare Limited | $1.0B | -10.9 | -4.2 | -0.3 | -30.8 | 10.6 | 7 | BEARISH | -23.4 |
| MEOBF Mesoblast Limited | $2.0B | -29.8 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| BIOGY BioGaia AB (publ) | $1.3B | 31.7 | 31.8 | 52.6 | 27.5 | 13.1 | 5 | BEARISH | 19.9 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.7 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -316.1 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 12.8 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| TRLV Trulieve Cannabis Corp. | $1.8B | — | — | — | — | — | — | BEARISH | — |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 7.8 | 4.5 | 6.7 | 13.0 | -2.1 | 6 | BEARISH | 0.8 |
| HROW Harrow Health, Inc. | $1.1B | -29.3 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -24.5 |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| STTK Shattuck Labs, Inc. | $550M | -11.3 | -39.2 | -29.3 | — | -66.6 | 4 | BEARISH | 200.5 |
| BNTC Benitec Biopharma Inc. | $300M | -8.9 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -35.5 |
| PPTDF PeptiDream Inc. | $870M | -39.5 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.0 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 14.9 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | BEARISH | -13.4 |
| WGS GeneDx Holdings Corp. | $1.7B | -17.2 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -51.3 |
| CSPHF CStone Pharmaceuticals | $1.4B | -15.0 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 807.7 |
| OMDA Omada Health | $1.2B | 280.0 | 1.8 | -1.5 | 6.0 | 404.7 | 7 | BEARISH | -26.5 |
| SMSZF SMS Co., Ltd. | $700M | -14.7 | -40.8 | 31.1 | 18.4 | 6.9 | 6 | BEARISH | 0.0 |
| ZRSEF DocMorris AG | $520M | -10.1 | -30.1 | -29.3 | -8.9 | 11.0 | 2 | BEARISH | 0.0 |
| DCTH Delcath Systems, Inc. | $500M | 1340.9 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 44.2 |
| EOLS Evolus, Inc. | $460M | -14.2 | 138.6 | -20.7 | -9.6 | 13.9 | 5 | BEARISH | 8.5 |
| EBS Emergent BioSolutions Inc. | $320M | -1.9 | -40.3 | -5.5 | -76.9 | -9.6 | 5 | BEARISH | -31.5 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.0 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -28.8 |
| EXETF Extendicare Inc. | $1.9B | 20.4 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 74.0 |
| ALHC Alignment Healthcare, Inc. | $1.7B | 40.4 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -54.0 |
| TKNO Alpha Teknova, Inc. | $340M | -22.6 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | BEARISH | 25.2 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.7 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| IDRSF Idorsia Ltd | $1.4B | -3.4 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| VBIZF Viva Biotech Holdings | $400M | 13.9 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.8 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.5 | -35.4 | -415.6 | — | — | 4 | BEARISH | 43.4 |
| SVRA Savara Inc. | $870M | -8.4 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 11.5 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.4 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.7 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| GALNF Galenica AG | $5.0B | 27.7 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.2 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -20.1 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 14.7 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | BEARISH | -24.5 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -28.7 |
| KURA Kura Oncology, Inc. | $850M | -2.9 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 2.1 |
| ATTO Attovia Therapeutics, Inc. | $630M | -16.1 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 272.2 |
| OCS Oculis Holding AG | $490M | -4.6 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.1 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.8 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -17.4 |
| WHTCF WELL Health Technologies Corp. | $770M | 162.1 | 0.5 | 5.4 | -2.7 | 38.6 | 6 | BEARISH | -17.4 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $710M | 9.0 | 14.3 | 13.4 | 11.4 | 22.0 | 4 | BEARISH | -22.7 |
| AURA Aura Biosciences, Inc. | $650M | -3.5 | -53.5 | -1360.0 | — | — | 4 | BEARISH | 7.5 |
| SENS Senseonics Holdings, Inc. | $400M | -3.7 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | BEARISH | 18.8 |
| TTRX Turn Therapeutics Inc. | $310M | -35.8 | -952.4 | 115.0 | — | — | 2 | BEARISH | 105.1 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -611.7 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| GHRS GH Research PLC | $1.2B | -20.0 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 43.5 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -1.6 |
| GNNSF Genscript Biotech Corporation | $9.6B | -15.7 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| HYPMY Hypera S.A. | $3.8B | 8.0 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| ANL Adlai Nortye Ltd. | $560M | -5.5 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 549.1 |
| AUNA Auna S.A. | $380M | -17.3 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | BEARISH | -21.1 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -21.1 |
| SMTI Sanara MedTech Inc. | $300M | -8.8 | -147.7 | 19.8 | -1.6 | 12.9 | 5 | BEARISH | 5.7 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| CMOPF Cosmo N.V. | $1.1B | -159.5 | -1.2 | -2.9 | -9.5 | -43.8 | 1 | BEARISH | -22.4 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.8 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.3 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -22.5 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -5.0 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.8 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -36.8 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.2 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -17.2 |
| ALMS Alumis Inc. | $880M | -1.7 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 47.2 |
| SANA Sana Biotechnology, Inc. | $700M | -3.3 | -152.9 | -242.3 | — | — | 3 | BEARISH | -55.8 |
| CAMRF Camurus AB | $3.7B | 58.8 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -31.3 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $1.0B | 11.2 | 6.5 | -1.9 | 20.2 | 10.7 | 6 | BEARISH | -2.4 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.1 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.4 | -49.2 | -201.4 | — | — | 3 | BEARISH | 110.7 |
| DSGN Design Therapeutics, Inc. | $640M | -9.0 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 85.5 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 15.9 | 10.0 | 11.6 | 2.2 | 46.6 | 7 | BEARISH | 0.9 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 1.3 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -5.6 | -41.0 | 583.9 | — | — | 2 | BEARISH | 2.0 |
| MNKD MannKind Corporation | $1.0B | -23.6 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | BEARISH | -38.0 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.9 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -4.3 |
| WVE Wave Life Sciences Ltd. | $630M | -3.2 | -80.0 | -1243.7 | -470.5 | -35.1 | 4 | BEARISH | -51.6 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.8 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| NVCR Novocure Ltd | $1.7B | -11.2 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 6.3 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 18.2 |
| LTGO Latigo Biotherapeutics Inc. | $900M | — | — | — | — | — | — | BEARISH | — |
| MTLZF Metall Zug AG | $680M | -34.7 | -2.8 | -1.4 | -5.6 | -0.3 | 6 | BEARISH | 0.0 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.5 | -845.0 | 24.6 | — | — | 2 | BEARISH | 38.6 |
| HELP Helus Pharma Inc. | $630M | -2.5 | -56.3 | -143.0 | — | — | 2 | BEARISH | — |
| IRWD Ironwood Pharmaceuticals, Inc. | $570M | 4.4 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 111.5 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 18.6 |
| VRNO Verano Holdings Corp | $370M | -1.4 | -4.5 | 1.5 | -6.0 | — | 3 | BEARISH | — |
| NPRRF Nipro Corporation | $1.4B | — | — | — | — | — | — | BEARISH | 5.8 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.9 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| ETON Eton Pharmaceuticals, Inc. | $1.4B | 110.0 | 36.0 | 33.3 | 30.8 | 81.5 | 7 | BEARISH | 177.1 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 219.4 |
| SLDB Solid Biosciences Inc. | $630M | -3.2 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 10.1 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.8 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.3 | -52.7 | 585.3 | — | — | 2 | BEARISH | -12.3 |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 4.6 |
| BWAY BrainsWay Ltd. | $440M | 46.9 | 13.0 | 31.1 | 15.8 | 32.3 | 5 | BEARISH | 38.3 |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.8 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -42.7 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -64.9 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.8 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| BFLY Butterfly Network, Inc. | $1.8B | -25.5 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | BEARISH | 231.8 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.3 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| OMER Omeros Corporation | $1.2B | 9.2 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.7 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.1 | -214.6 | 174.4 | — | — | 1 | BEARISH | 197.4 |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.4 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 5.5 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.7 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -55.7 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -7.0 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 29.4 |
| BLTE Belite Bio, Inc | $5.9B | -52.8 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| YPHDF Ypsomed Holding AG | $5.7B | 24.2 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.8 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.6 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| CURLF Curaleaf Holdings, Inc. | $1.8B | -61.9 | -4.2 | 0.5 | 3.7 | 2.7 | 7 | BEARISH | -2.1 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.5 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| MEDOF Medios AG | $1.3B | 23.5 | 2.1 | 2.8 | 0.6 | 10.0 | 6 | BEARISH | 0.0 |
| CSBTF Kuros Biosciences AG | $950M | 113.3 | 9.6 | 9.2 | 4.8 | 29.1 | 4 | BEARISH | -39.6 |
| MGTX MeiraGTx Holdings plc | $880M | 12.4 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 7.8 |
| INMD InMode Ltd. | $800M | 10.9 | 12.3 | 44.5 | 17.9 | -6.7 | 5 | BEARISH | -11.3 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.8 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 24.4 |
| CLYM Climb Bio, Inc. | $590M | -11.5 | -27.1 | -88.6 | — | — | 2 | BEARISH | 380.9 |
| AVR Anteris Technologies Global Corp. | $570M | -2.2 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 20.0 |
| MDXG MiMedx Group, Inc. | $570M | 97.5 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.7 | -19.5 | 523.8 | — | — | 2 | BEARISH | -11.9 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 29.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| HBMHF HBM Holdings Limited | $1.3B | 12.7 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| RAFLF Raffles Medical Group Ltd | $1.2B | 22.4 | 5.8 | 7.3 | 8.2 | -2.8 | 7 | BEARISH | -20.0 |
| MCRPF MicroPort Scientific Corp. | $1.1B | 31.2 | 6.1 | -1.7 | 21.3 | -3.5 | 5 | BEARISH | -63.2 |
| EBOSY EBOS Group Limited | $1.0B | 15.1 | 5.0 | 4.4 | 1.7 | -8.1 | 6 | BEARISH | -47.5 |
| GERN Geron Corporation | $720M | -11.5 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -7.3 |
| XVIPY Xvivo Perfusion AB (publ) | $690M | 49.0 | 5.9 | 4.6 | 17.7 | 17.5 | 6 | BEARISH | — |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| GYRE Gyre Therapeutics, Inc. | $620M | -32.8 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BEARISH | -20.1 |
| ANNX Annexon, Inc. | $610M | -3.2 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 17.1 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| SSII SS Innovations International, Inc. | $450M | -38.3 | -26.1 | -15.6 | -19.1 | 108.5 | 3 | BEARISH | -72.1 |
| ASMB Assembly Biosciences, Inc. | $400M | 36.9 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -30.6 |
| SWDCF Swedencare AB (publ) | $370M | 35.5 | 1.2 | 1.7 | 3.9 | 1.4 | 7 | BEARISH | -46.5 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.5 | -55.7 | 460.5 | — | — | 3 | BEARISH | 52.9 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.6 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| NHC National HealthCare Corporation | $3.7B | 23.5 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 72.6 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 96.1 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| IRMD IRadimed Corporation | $1.1B | 46.1 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 7.8 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.5 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -5.2 |
| AQST Aquestive Therapeutics, Inc. | $500M | -6.3 | 121.1 | 43.4 | -165.5 | 22.6 | 5 | BEARISH | -40.5 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 168.4 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 20.8 |
| RMYHY Ramsay Health Care Limited | $9.2B | 41.0 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -113.1 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.4 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.5 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| ARSUF Fagron N.V. | $2.0B | 18.9 | 16.7 | 10.8 | 8.4 | 11.8 | 4 | BEARISH | 9.8 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.1 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| SNDA Sonida Senior Living, Inc. | $1.6B | -5.3 | -25.2 | -2.9 | -11.8 | 49.4 | 4 | BEARISH | 23.9 |
| ELEAF EL.En. S.p.A. | $1.4B | 13.8 | 13.2 | 29.1 | 6.0 | 25.8 | 8 | BEARISH | 37.9 |
| MDCLF MedinCell S.A. | $1.1B | -29.5 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| IART Integra LifeSciences Holdings Corporation | $930M | 71.5 | 1.2 | 13.4 | 3.6 | 0.8 | 6 | BEARISH | -25.6 |
| IMMX Immix Biopharma, Inc. | $680M | -9.1 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 123.0 |
| CADL Candel Therapeutics, Inc. | $610M | -5.9 | -81.8 | 219.4 | — | — | 2 | BEARISH | 52.8 |
| GNFTF Genfit S.A. | $470M | -5.5 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| VREOF Vireo Growth Inc. | $310M | -4.1 | -4.6 | -0.7 | -0.0 | — | 3 | BEARISH | — |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.3 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.0 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.9 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 7.7 |
| ADDLF AddLife AB (publ) | $1.9B | 34.3 | 11.3 | 7.0 | 4.9 | 1.1 | 4 | BEARISH | -62.5 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| VIMGF Vimian Group AB (publ) | $1.5B | 48.7 | 5.4 | 6.4 | 7.4 | 8.9 | 7 | BEARISH | -8.0 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| GTBIF Green Thumb Industries Inc. | $1.4B | 11.7 | 7.0 | 2.5 | 1.6 | 4.8 | 7 | BEARISH | -16.3 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -18.3 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.4 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 1.2 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.5 | 5.7 | 8.4 | 19.4 | 24.4 | 6 | BEARISH | 20.0 |
| AKTS Aktis Oncology, Inc. | $850M | -15.7 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 373763.6 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $820M | -4.9 | -4.9 | 0.0 | -14.3 | 5.6 | 6 | BEARISH | -40.3 |
| ARDX Ardelyx, Inc. | $770M | -13.3 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -40.5 |
| TGRNF Tong Ren Tang Technologies Co. Ltd. | $660M | 10.6 | 4.1 | 12.2 | 8.2 | -18.2 | 6 | BEARISH | -43.0 |
| CRWRF Craneware plc | $620M | 25.9 | 6.0 | 6.8 | 9.7 | 4.2 | 7 | BEARISH | -43.9 |
| EVOTF Evotec SE | $590M | -2.7 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | BEARISH | -54.3 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.1 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.1 |
| KSRBF Kossan Rubber Industries Bhd | $480M | 17.0 | 5.0 | 8.5 | 11.3 | 1.0 | 5 | BEARISH | -43.2 |
| PROK ProKidney Corp. | $470M | -2.7 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.5 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.8 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 2.5 |
| AVCTF Avacta Group Plc | $420M | -6.8 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.7 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.1 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | -1.6 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -1.9 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.3 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 18.0 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.5 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| BRCTF BioArctic AB | $2.6B | 265.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.8 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -46.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.9 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 19.1 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| ULIHF The United Laboratories International Holdings Limited | $1.9B | 21.1 | 3.3 | 4.4 | 5.6 | -16.6 | 4 | BEARISH | -49.9 |
| FDMDF 4DMedical Limited | $1.6B | -8.7 | -174.5 | 43.4 | -1194.8 | 20.5 | 3 | BEARISH | 94.2 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 105.4 | 7.3 | 6.9 | -5.7 | 103.7 | 4 | BEARISH | -14.3 |
| TTALF Terveystalo Oyj | $910M | 13.4 | 10.3 | 6.3 | 2.1 | -8.7 | 4 | BEARISH | -44.5 |
| IVEVF Inventiva S.A. | $750M | -6.4 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| NNCSF Nanosonics Limited | $620M | 50.8 | 8.3 | 15.6 | 8.1 | 2.4 | 4 | BEARISH | -39.9 |
| RGNX REGENXBIO Inc. | $440M | -1.7 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -49.4 |
| CALZF PolyNovo Limited | $430M | 81.6 | 8.4 | 9.3 | 10.0 | 12.8 | 7 | BEARISH | -38.6 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -46.0 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -61.6 |
| NIKA Nika Pharmaceuticals Inc. | $370M | -4711.6 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 8.5 |
| TLRY Tilray Brands, Inc. | $310M | -2.0 | -8.8 | -3.4 | -16.8 | -16.9 | 3 | BEARISH | -81.4 |
| DMTRF 3-D Matrix, Ltd. | $310M | 12.4 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
PSNL vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F